T1	Participants 55 76	chronic heart failure
T2	Participants 189 222	patients with heart failure (HF).
T3	Participants 272 283	HF patients
T4	Participants 322 378	7788 patients in the Digitalis Investigation Group trial
T5	Participants 1785 1820	ambulatory patients with chronic HF
